Effective April 1, 2010, Novolin®, Novolog®, Lantus®, and Levemir® will be the preferred brands of insulin for all prescription drug programs, and they will be the only brands of insulin available on the Select Drug Program® Formulary.
In addition, all new prescriptions for Humulin®, Humalog®, ReliOn®/Novolin®, and Apidra® insulin will require prior authorization. Prior authorization requests will be reviewed in accordance with our established criteria, and, if approved, non-preferred insulin will be covered at the highest level of cost-sharing. If denied, non-preferred insulin will not be a covered benefit. To learn more about our pharmacy policy and prior authorization criteria for insulin, visit the Pharmacy Policy section of our website at www.ibx.com/rxpolicy. The policy will be available April 1, 2010.
Please note that members who are currently taking Humulin®, Humalog®, ReliOn®/Novolin®, and Apidra® insulin will not be required to obtain prior authorization until July 1, 2010.
Controlling overall health care costs for everyone — members, employer groups, and the community — and improving the lives of those affected by conditions such as diabetes is our top priority. By selecting preferred brands of insulin, we are better positioned to control costs while still providing your patients, our members, with access to effective medications.
If you have any questions about these changes, please contact FutureScripts, our pharmacy benefits management company, at 1-888-678-7012.